Where does pCPA fit?

The pan-Canadian Pharmaceutical Alliance (pCPA) is one part of the overall Canadian drug approval and reimbursement process.

*Please note that the figure above is a simplified illustration of the process and there can be exceptions.

Step 1: Health Canada

Health Canada reviews drugs for safety, efficacy and quality before authorizing them for sale in Canada. Health Canada approved Luxturna in October 2020.

Step 2: CADTH & INESSS

In Canada there are two health technology assessment organizations which review the clinical and cost-effectiveness of a drug product; the Canadian Agency for Drugs and Technologies in Health (CADTH) and in Quebec, l’Institut national d’excellence en santé et en services sociaux (INESSS). CADTH and INESSS provide a recommendation to public drug plans on whether or not a drug should be reimbursed for public funding. CADTH and INESSS recommended that Luxturna should be publicly funded in November 2020.

Step 3: Price Negotiation

If a treatment has been recommended for funding by CADTH the provinces will then start to negotiate the price and the terms of sale with the pharmaceutical company. The pan-Canadian pharmaceutical Alliance (pCPA) is an alliance of provincial and federal governments who work together to negotiate these terms with the pharmaceutical company. After almost a year, pCPA began negotiating for access to Luxturna on November 25, 2021.

Step 4: Your Provincial Ministry of Health & Federal drug programs

Each province has their own Public Drug Plan. Once the p-CPA negotiation has been completed, each province makes a final decision to fund a drug and enters into its own separate agreement with the drug manufacturer. This process hasn’t yet started for Luxturna

Fighting Blindness Canada, our vision partners and the vision loss community have been actively advocating for access to Luxturna, and clear a path forward for future treatments to be publicly funded.  Your help is needed now.

TIME = SIGHT and we can not let a bureaucratic process slow down access.